Liposomes and nanotechnology in drug development: Focus on neurological targets

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 951-960

  Ramos Cabrer, Pedro ^a   Campos, Francisco ^a  

^a Pediatric Nutrition Research Group Health Research Institute of Santiago de Compostela   (Spain)

Author keywords

Blood brain barrier; Brain; Central nervous system; Nanotechnology; Theranostics

Indexed keywords

CITICOLINE; DENDRIMER; GADOLINIUM; LIPOSOME; NANOCAGE; NANOCAPSULE; NANOPARTICLE; NANOSPHERE; NANOTUBE; RHODAMINE;

BLOOD BRAIN BARRIER; BRAIN ISCHEMIA; DRUG TRANSPORT; FLUORESCENCE MICROSCOPY; HUMAN; ISOTOPE LABELING; LIPOSOMAL DELIVERY; MICELLE; MOLECULAR IMAGING; NANOANALYSIS; NANOPHARMACEUTICS; NANOPROBE; NANOTECHNOLOGY; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PERSONALIZED MEDICINE; REVIEW; SIGNAL DETECTION; STRUCTURE ANALYSIS; THERANOSTICS; TRAUMATIC BRAIN INJURY;

BLOOD-BRAIN BARRIER; BRAIN; CENTRAL NERVOUS SYSTEM; NANOTECHNOLOGY; THERANOSTICS;

BLOOD-BRAIN BARRIER; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; NANOMEDICINE; NERVOUS SYSTEM DISEASES;

EID: 84874921396     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S30721     Document Type: Review

References (48)

1. Hofman A, van Duijn CM, Franco OH, et al. The Rotterdam Study: 2012 objectives and design update. Eur J Epidemiol. 2011;26:657-686.
2. Greenhalgh AD, Ogungbenro K, Rothwell NJ, Galea JP. Translational pharmacokinetics: challenges of an emerging approach to drug development in stroke. Expert Opin Drug Metab Toxicol. 2011;7:681-695.
3. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis. 2010;37:13-25.
4. Ballabh P, Braun A, Nedergaard M. The blood-brain barrier: an overview. Structure, regulation, and clinical implications. Neurobiol Dis. 2004;16:1-13.
5. Schinkel AH. P-glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev. 1999;36:179-194.
6. Abbott NJ, Romero IA. Transporting therapeutics across the blood-brain barrier. Mol Med Today. 1996;2:106-113.
7. Dhuria SV, Hanson LR, Frey WH 2nd. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci. 2010;99:1654-1673.
8. Gabathuler R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol Dis. 2010;37:48-57.
9. Borlongan CV, Emerich DF. Facilitation of drug entry into the CNS via transient permeation of blood brain barrier: laboratory and preliminary clinical evidence from bradykinin receptor agonist, Cereport. Brain Res Bull. 2003;60:297-306.
10. Meairs S, Alonso A. Ultrasound, microbubbles and the blood-brain barrier. Prog Biophys Mol Biol. 2007;93:354-362.
11. Suzuki M, Iwasaki Y, Yamamoto T, Konno H, Kudo H. Sequelae of the osmotic blood-brain barrier opening in rats. J Neurosurg. 1988;69: 421-428.
12. Diringer MN, Zazulia AR. Osmotic therapy: fact and fiction. Neurocrit Care. 2004;1:219-233.
13. Vlieghe P, Khrestchatisky M. Medicinal chemistry based approaches and nanotechnology-based systems to improve CNS drug targeting and delivery. Med Res Rev. March 20, 2012. [Epub ahead of print.]
14. Rautio J, Laine K, Gynther M, Savolainen J. Prodrug approaches for CNS delivery. AAPS J. 2008;10:92-102.
15. Bitounis D, Fanciullino R, Iliadis A, Ciccolini J. Optimizing druggability through liposomal formulations: new approaches to an old concept. ISRN Pharm. February 9, 2012. Article 738432.
16. Wagner A, Vorauer-Uhl K. Liposome technology for industrial purposes. Journal of Drug Delivery. 2011;2011:Article ID 591325.
17. Wang LS, Chuang MC, Ho JA. Nanotheranostics-a review of recent publications. Int J Nanomedicine. 2012;7:4679-4695.
18. Mulder WJ, Strijkers GJ, van Tilborg GA, Griffioen AW, Nicolay K. Lipid-based nanoparticles for contrast-enhanced MRI and molecular imaging. NMR Biomed. 2006;19:142-164.
19. Ramos-Cabrer P, Agulla J, Argibay B, Pérez-Mato M, Castillo J. Serial MRI study of the enhanced therapeutic effects of liposome-encapsulated citicoline in cerebral ischemia. Int J Pharm. 2011;205:228-233.
20. Fernandez-Fernandez A, Manchanda R, McGoron AJ. Theranostic applications of nanomaterials in cancer: drug delivery, image-guided therapy, and multifunctional platforms. Appl Biochem Biotechnol. 2011;165:1628-1651.
21. Lobatto ME, Fuster V, Fayad ZA, Mulder WJM. Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nat Rev Drug Discov. 2011;10:835-852.
22. Shim MS, Kwon YJ. Stimuli-responsive polymers and nanomaterials for gene delivery and imaging applications. Adv Drug Deliv Rev. 2012;64: 1046-1059.
23. Ramos-Cabrer P, Campos F, Sobrino T, Castillo J. Targeting the ischemic penumbra. Stroke. 2011;42(Suppl 1):S7-S11.
24. Adibhatla RM, Hatcher JF. Cytidine 5′-diphosphocholine (CDP-choline) in stroke and other CNS disorders. Neurochem Res. 2005;30:15-23.
25. Adibhatla RM, Hatcher JF, Tureyen K. CDP-choline liposomes provide significant reduction in infarction over free CDP-choline in stroke. Brain Res. 2005;1058:193-197.
26. Fresta M, Puglisi G. Biological effects of CDP-choline loaded long circulating liposomes on rat cerebral post-ischemic reperfusion. Int J Pharm. 1996;134:89-97.
27. Fresta M, Puglisi G. Survival rate improvement in a rat ischemia model by long circulating liposomes containing cytidine-5I-diphosphate choline. Life Sci. 1997;61:1227-1235.
28. Fresta M, Puglisi G. Reduction of maturation phenomenon in cerebral ischemia with CDP-choline-loaded liposomes. Pharm Res. 1999;16: 1843-1849.
29. Fresta M, Puglisi G, Di Giacomo C, Russo A. Liposomes as in-vivo carriers for citicoline: effects on rat cerebral post-ischaemic reperfusion. J Pharm Pharmacol. 1994;46:974-981.
30. Puglisi G, Fresta M, La Rosa C, Ventura CA, Panico AM, Mazzone G. Liposomes as a potential drug carrier for citicoline (CDP-choline) and the effect of formulation conditions on encapsulation efficiency. Pharmazie. 1992;47:211-215.
31. Davalos A, Alvarez-Sabin J, Castillo J, et al. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet. 2012;380:349-357.
32. Clark WM, Clark TD. Stroke: treatment for acute stroke-the end of the citicoline saga. Nat Rev Neurol. 2012;8:484-485.
33. Clark WM. Efficacy of citicoline as an acute stroke treatment. Expert Opin Pharmacother. 2009;10:839-846.
34. Bustamante A, Giralt D, Garcia-Bonilla L, et al. Citicoline in pre-clinical animal models of stroke: a meta-analysis shows the optimal neuroprotective profile and the missing steps for jumping into a stroke clinical trial. J Neurochem. 2012;123:217-225.
35. Zafonte RD, Bagiella E, Ansel BM, et al. Effect of citicoline on functional and cognitive status among patients with traumatic brain injury: Citicoline Brain Injury Treatment Trial (COBRIT). JAMA. 2012;308:1993-2000.
36. Fischer HC, Chan WC. Nanotoxicity: the growing need for in vivo study. Curr Opin Biotechnol. 2007;18:565-571.
37. Lo EH. A new penumbra: transitioning from injury into repair after stroke. Nat Med. 2008;14:497-500.
38. Widder KJ, Senyel AE, Scarpelli GD. Magnetic microspheres: model system of site specific drug delivery in vivo. Proc Soc Exp Biol Med. 1978;158:141-146.
39. Laurent S, Forge D, Port M, et al. Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chem Rev. 2008;108:2064-2110.
40. Mikhaylov G, Mikac U, Magaeva AA, et al. Ferri-liposomes as an MRI-visible drug-delivery system for targeting tumours and their microenvironment. Nat Nanotechnol. 2011;6:594-602.
41. Plank C, Zelphati O, Mykhaylyk O. Magnetically enhanced nucleic acid delivery. Ten years of magnetofection-progress and prospects. Adv Drug Deliv Rev. 2011;63:1300-1331.
42. Malhotra M, Tomaro-Duchesneau C, Prakash S. Synthesis of TAT peptide-tagged PEGylated chitosan nanoparticles for siRNA delivery targeting neurodegenerative diseases. Biomaterials. 2013;34:1270-1280.
43. Lista S, Faltraco F, Hampel H. Biological and methodical challenges of blood-based proteomics in the field of neurological research. Prog Neurobiol. 2013;101-102:18-34.
44. Zhang J, Keene CD, Pan C, Montine KS, Montine TJ. Proteomics of human neurodegenerative diseases. J Neuropathol Exp Neurol. 2008;67: 923-932.
45. Matsuda H, Imabayashi E. Molecular neuroimaging in Alzheimer's disease. Neuroimaging Clin N Am. 2012;22:57-65.
46. Seibyl J, Russell D, Jennings D, Marek K. Neuroimaging over the course of Parkinson's disease: From early detection of the at-risk patient to improving pharmacotherapy of later-stage disease. Semin Nucl Med. 2012;42:406-414.
47. Lossinsky AS, Shivers RR. Structural pathways for macromolecular and cellular transport across the blood-brain barrier during inflammatory conditions. Histol Histopathol. 2004;19:535-564.
48. Chen X, Wong R, Khalidov I, et al. Inflamed leukocyte-mimetic nanoparticles for molecular imaging of inflammation. Biomaterials. 2011;32:7651-7661.